
Dr John Hood Highlights Advantages of IPF Hedgehog Inhibitor ENV-101
John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).
While at the
Transcript
What are the potential advantages of ENV-101 over existing therapies for IPF?
There's currently 2 approved drugs for IPF, pirfenidone and nintedanib, both which only incrementally slow the progression of the disease. And they have tolerability issues as well. They have GI [gastrointestinal] toxicity and they're not very efficacious. In contrast,
What are some unmet needs and current gaps of knowledge in IPF, and how can health care systems address these issues?
The biggest unmet medical need is we just don't have a therapy that makes patients better. Ultimately, that's what we're trying to do at Endeavor. We have a drug that, at least to date, is showing evidence that patients get better. As far as what the health care system can do, they're somewhat limited because they simply don't have the tools in the toolbox yet. The current therapies are ineffectual and intolerable, so most patients don't even stay on drug. Roughly only 20% of patients are on current standard of care, and there's a high discontinuation rate. We're trying to make it much, much easier for the health care system by giving them something that works.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.